INSERM 669, Paris-Sud University and Paris-Descartes University, Maison des Adolescents, 97, boulevard de Port-Royal, 75014 Paris, France.
INSERM 669, Paris-Sud University and Paris-Descartes University, Maison des Adolescents, 97, boulevard de Port-Royal, 75014 Paris, France.
Eur Psychiatry. 2014 Mar;29(3):183-90. doi: 10.1016/j.eurpsy.2013.03.001. Epub 2013 Jun 12.
The PAtient SAtisfaction with Psychotropic (PASAP) scale is a self-completed questionnaire measuring satisfaction with psychotropic medication. The aim of the study was to describe its development in French and its psychometric properties.
Scale construction was based on an extensive search of the literature. The item reduction process required semi-structured interviews of psychiatric outpatients (n=30). The final version of the PASAP is a 9-item, 5-point Likert-type scale, covering the scope of effectiveness and adherence. To assess the psychometric properties of the scale, French patients with an acute manic episode (n=314) from a large European observational cohort completed the PASAP scale 3 months after psychotropic treatment initiation/change. Internal validity and reliability were assessed using principal component analysis (PCA). Concurrent validity was assessed using comparisons to physician-rated satisfaction with life, illness severity, mood relapse, compliance and side effects.
Participation rate was 68.4%. PCA was in favour of uni-dimensionality. Cronbach's α coefficient was 0.85 (95%CI 0.83-0.88). All five concurrent measures were significantly associated with the PASAP score.
The PASAP scale showed good psychometric properties in a large bipolar population and thus seems adequate for evaluating treatment satisfaction. Its short length and good acceptability makes it suitable for clinical research.
精神药物治疗患者满意度量表（PASAP）是一种自我完成的问卷，用于衡量对精神药物的满意度。本研究的目的是描述其在法语中的开发过程及其心理测量学特性。
量表的构建基于对文献的广泛搜索。项目删减过程需要对 30 名精神科门诊患者进行半结构化访谈。PASAP 的最终版本是一个 9 项 5 级李克特量表，涵盖了疗效和依从性的范围。为了评估量表的心理测量特性，来自一个大型欧洲观察性队列的 314 名急性躁狂发作的法国患者在开始/改变精神药物治疗 3 个月后完成了 PASAP 量表。使用主成分分析（PCA）评估内部有效性和可靠性。同时效性通过与医生评定的生活满意度、疾病严重程度、情绪复发、依从性和副作用进行比较来评估。
参与率为 68.4%。PCA 有利于单维度。克朗巴赫α系数为 0.85（95%CI 0.83-0.88）。所有五个同时效测量都与 PASAP 评分显著相关。
在大型双相情感障碍人群中，PASAP 量表表现出良好的心理测量特性，因此似乎适合评估治疗满意度。其简短的长度和良好的可接受性使其适用于临床研究。
